BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said the Japanese Patent Office has granted a key patent for its lead anti-cancer drug, BVX001, significantly bolstering its intellectual property portfolio.
This follows the company's recent success in securing similar protection from the United States Patent and Trademark Office (USPTO).
BVX001 is a targeted drug candidate designed to treat acute myeloid leukaemia.
"With plans to prosecute in a further six global jurisdictions, we are building strong protection for our lead therapeutic asset, at the broadest level, enhancing the value of BVX001 as we prepare for first in human studies and refine the optimal drug development and commercialisation strategy," said chief executive Tiffany Thorn.